A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease (original) (raw)

2000

Abstract

Article abstract—Objective: To investigate the efficacy and safety of donepezil in patients with moderate to severe AD (standardized Mini-Mental State Examination (sMMSE) scores of 5 to 17; Functional Assessment Staging score 6a t baseline). Methods: Two-hundred ninety patients were randomized to treatment in this 24-week, double-blind, placebo- controlled trial. Patients received either donepezil 5 mg/day for the first 28 days

Jane Hecker hasn't uploaded this paper.

Let Jane know you want this paper to be uploaded.

Ask for this paper to be uploaded.